All News

December 05 2016

Israeli teachers at CIME

  • Education
  • Life @ MINATEC
  • News
As part of the EU EduNano project, eight Israeli high-school teachers will come to CIME Nanotech in mid-December to expand their knowledge and discuss teaching methods with the Nano@school team. The program includes nano-biotech, atomic force microscopy, and PV characterization lab classes and even classes taught right in the clean room! In July, CIME hosted […] >>

December 05 2016

Alps Design Lab, where technology meets design

  • Education
  • Innovation & Society
  • News
Alps Design Lab, a CEA Tech Open Lab, has tackled the challenge of how to use a shipping-container-sized electrolyzer to create a “normal-sized” teaching demonstrator. In a few weeks, the lab will deliver to Liten a refrigerator-sized system that packs in a high-temperature furnace, heat exchanger, and steam generator—qualities sure to appeal to future users! […] >>

December 05 2016

Morphosense precision structural-health monitoring

  • Industry
  • Innovation & Society
  • MINATEC
  • News
In the future, major structures like bridges, dams, tunnels, railroad tracks, oceangoing vessels, cooling towers, and wind-turbine blades could be instrumented with Morphosense’s MEMS accelerometer networks. Morphosense is a Leti spinoff founded in mid-2016 to develop a precision structural-health monitoring system leveraging ten years of R&D. The system, which consists of sensors mounted at strategic […] >>

December 05 2016

Photonics platform delivery date pushed back

  • Life @ MINATEC
  • News
Delivery of the six-level, 12,800 sq. m photonics platform was originally scheduled for early November, but has been pushed back to January due to construction delays and the results of certain tests. The contractor that won the bid will have to put additional resources on the job to complete construction. The CEA has set up […] >>

December 05 2016

PX’Therapeutics focuses on new drug candidate

  • Industry
  • Life @ MINATEC
  • MINATEC
  • News
  • Research
In the future, diabetics suffering from neuropathy (in their hands and feet, for example) could benefit from a new drug called atexakin, which regenerates damaged nerve fibers. Switzerland’s Relief Therapeutics Holding AG recently signed an agreement with Merck to develop, manufacture, and commercialize the drug. Merck then turned to Grenoble’s PX’Therapeutics to develop an efficient […] >>
More information
X